Cancer is currently one of the principal foci for Precision Medicine and exemplifies the opportunities and challenges for the discipline. Our team have been pivotal to the establishment of large epidemiological research resources that are now being utilized to address key questions in cancer research. Highly selected groups of men women are participating in our studies to support the identification of heritable risk factors (genetic and epigenetic) and large population-based samples of men and women are enabling research to further characterise the prevalence and penetrance of risk factors to enable clinical translation of new information and inform healthcare policy.
With an initial focus on common cancers such as breast and prostate cancer we now aim to impact key stages across the disease and life course, including:
defining the best molecular tests for placing each man and woman individually and accurately on the breast or prostate cancer risk spectrum throughout life.
defining the best molecular tests for early detection, targeted therapies, prognostication and disease monitoring throughout the disease course.
devise best practice guidelines and drive necessary policy change.
develop a workforce trained in the environment anticipated for future clinical research that demands a knowledge base and connection from basic research through to clinical outcomes that integrates molecular data at all decision points across the life and disease course. Our work is therefore also providing the foundation for the emerging Precision Pubic Health era.